VANCOUVER, BC, June 5, 2023
/PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the
"Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company
advancing innovative treatments and safe, evidence-based
psychedelic-assisted therapies, is pleased to announce Cedar
Clinical Research (CCR) is a top research site for MindMed's Phase
2b study evaluating MM-120 (lysergide
D-tartrate) for General Anxiety Disorder.
CCR's research clinic in Draper,
Utah, is the top enrolling site for the research study –
having enrolled and dosed 19 clinical trial participants for the
study to date. CCR also recently began enrolling volunteers for
this trial at a second research clinic – in Murray, Utah.
"We're excited to support MindMed in their clinical trial work,
by evaluating new important treatments and protocols to address
mental health disorders," said Paul
Thielking, Chief Science Officer, Numinus, and Principal
Investigator at CCR Murray. "The fact that our Draper research clinic is the top enrolling
site for the study underscores the quality of our clinical research
capabilities and recruiting efforts."
The MindMed study aims to enroll up to 200 participants who will
receive a single administration of 25 µg, 50 µg, 100 µg or 200 µg
of MM-120 or placebo. Topline results are expected to be announced
by MindMed in late 2023.
To learn more about the study, and find out if you qualify to
participate in it, please visit:
https://www.anxietyresearchstudy.com/
About Numinus
Numinus Wellness Inc. (TSX: NUMI) helps people to heal and be
well through the development and delivery of innovative mental
health care and access to safe, evidence-based psychedelic-assisted
therapies. The Numinus model - including psychedelic production,
research and clinic care - is at the forefront of a transformation
aimed at healing rather than managing symptoms for depression,
anxiety, trauma, pain and substance use. At Numinus, we are leading
the integration of psychedelic-assisted therapies into mainstream
clinical practice and building the foundation for a healthier
society.
Learn more at www.numinus.com and follow us
on LinkedIn, Facebook, Twitter,
and Instagram.
About MindMed
MindMed (NASDAQ: MNMD) (NEO: MMED) is a clinical stage
biopharmaceutical company developing novel products to treat brain
health disorders, with a particular focus on psychiatry, addiction,
pain and neurology. The company is developing a pipeline of
innovative drug candidates, with and without acute perceptual
effects, targeting the serotonin, dopamine and acetylcholine
systems.
Forward-looking
statements
Statements and other information contained in this press
release about anticipated future events constitute forward-looking
statements, including statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are often, but not always, identified by
the use of words such as "seek", "anticipate", "believe", "plan",
"estimate", "expect" and "intend" and statements that an event
"may", "will", "should", "could" or "might" occur or other similar
expressions. Forward-looking statements are subject to risks and
uncertainties and other factors that could cause actual results to
differ materially from those contained in the forward-looking
statements, including challenges and uncertainties inherent in
product and/or treatment development and in the psychedelics
industry generally, availably of suitable subjects, the
uncertainties of clinical success, possibility of adverse events,
and the timeline for the availability of the treatment under
investigation; the laws, challenges and risks involved in
production of a psychedelics drug; and the uncertainty of the level
of demand, uptake and/or insurance coverage for treatment other
risks that are set forth in (a) Numinus public disclosures
available on SEDAR at www.sedar.com, and (b) MindMed public
disclosures available on EDGAR at www.sec.gov/edgar.
Forward-looking statements are based on estimates and opinions of
the company's respective management at the date the statements are
made. Neither Mindmed nor Numinus undertake any obligation to
update forward-looking statements even if circumstances or
estimates or opinions should change except as required by
applicable laws. Investors should not place undue reliance on
forward-looking statements.
View original
content:https://www.prnewswire.com/news-releases/cedar-clinical-research-by-numinus-the-top-enrolling-clinical-research-site-for-mindmeds-phase-2b-study-evaluating-mm-120-301842011.html
SOURCE Numinus Wellness Inc.